New hope for kidney patients: drug safely lowers dangerous potassium levels
NCT ID NCT05136664
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called patiromer in 262 Chinese adults with chronic kidney disease and high potassium levels. Participants took patiromer for 4 weeks, then some switched to placebo for 8 weeks to see if potassium stayed controlled. The goal was to manage potassium safely while allowing patients to continue their heart-protective medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY, CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigator Site 001
Hangzhou, Zhejiang, 310003, China
-
Investigator Site 002
Changzhou, Jiangsu, 213004, China
-
Investigator Site 003
Lanzhou, Gansu, 730030, China
-
Investigator Site 004
Chengdu, Sichuan, 610044, China
-
Investigator Site 005
Xuzhou, Jiangsu, 221004, China
-
Investigator Site 006
Changsha, Hunan, 410013, China
-
Investigator Site 007
Changchun, Jilin, 130041, China
-
Investigator Site 008
Hefei, Anhui, 230601, China
-
Investigator Site 009
Hefei, Anhui, 230022, China
-
Investigator Site 010
Wuhan, Hubei, 430060, China
-
Investigator Site 011
Yuncheng, Shanxi, 044099, China
-
Investigator Site 012
Lanzhou, Gansu, 730013, China
-
Investigator Site 013
Zhenjiang, Jiangsu, 210031, China
-
Investigator Site 014
Tianjin, Tianjin Municipality, 300052, China
-
Investigator Site 015
Shanghai, Shanghai Municipality, 200040, China
-
Investigator Site 016
Beijing, Beijing Municipality, 100029, China
-
Investigator Site 018
Yinchuan, Ningxia, 750003, China
-
Investigator Site 019
Nanjing, Jiangsu, 210029, China
-
Investigator Site 020
Hanzhou, Zhejiang, 310014, China
-
Investigator Site 021
Wuxi, Jiangsu, 214023, China
-
Investigator Site 022
Taiyuan, Shanxi, 030012, China
-
Investigator Site 023
Ürümqi, Xinjiang, 830001, China
-
Investigator Site 024
Nanyang, Henan, 473000, China
-
Investigator Site 025
Jinhua, Zhejiang, 322000, China
-
Investigator Site 026
Jiaxing, Zhejiang, 314000, China
-
Investigator Site 027
Zhuzhou, Tianyuan District, 412007, China
-
Investigator Site 028
Shanghai, Pudong New Area, 200120, China
-
Investigator Site 030
Nanning, Guangxi, 530000, China